

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2025/129201 A9

(43) International Publication Date
19 June 2025 (19.06.2025)

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/28 (2006.01)
A61K 40/42 (2025.01)

(21) International Application Number:

PCT/US2024/060426

(22) International Filing Date:

16 December 2024 (16.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/610,917	15 December 2023 (15.12.2023)	US
63/654,930	31 May 2024 (31.05.2024)	US
63/708,461	17 October 2024 (17.10.2024)	US

(71) Applicant: **CAPSTAN THERAPEUTICS, INC.**
[US/US]; 9880 Campus Point Drive, Suite 220, San Diego,
CA 92121 (US).

(72) Inventors; and

(71) Applicants: **NGUYEN, Duy** [US/US]; 9880 Campus Point
Drive, Suite 220, San Diego, CA 92121 (US). **PRESTA,
Leonard, G.** [US/US]; 1900 Gough Street, #206, San Fran-
cisco, CA 94109 (US). **MARTINKO, Alexander** [US/US];
1835 9th Avenue, San Francisco, CA 94122 (US). **YONG,
Qian-Chen** [MY/US]; 9880 Campus Point Drive, Suite
220, San Diego, CA 92121 (US). **SIEVERS, Stuart, Aaron**
[US/US]; 15467 Lemay Street, Van Nuys, CA 91406 (US).

(74) Agent: **TA, My, Chau**; McDonnell Boehnen Hulbert &
Berghoff LLP, 300 S Wacker Dr, Chicago, IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- with information concerning authorization of rectification
of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))

(48) Date of publication of this corrected version:

07 August 2025 (07.08.2025)

(15) Information about Correction:

see Notice of 07 August 2025 (07.08.2025)

(54) Title: HUMANIZED ANTI-CD8 ANTIBODIES AND USES THEREOF

(57) Abstract: The present disclosure provides humanized antibodies and antigen binding domains thereof that bind CD8 α and other antibody formats comprising these antigen binding domains, their use as a targeting moiety on lipid nanoparticles (tLNP) to deliver a therapeutic payload (such as a nucleic acid molecule) or other types of payloads. The present disclosure further relates to pharmaceutical compositions comprising the humanized anti-CD8 α antibodies and CD8-targeted tLNP encapsulating a payload.



WO 2025/129201 A9